Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

SEGMENTED INFORMATION

v3.6.0.2
SEGMENTED INFORMATION
12 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
NOTE 15. SEGMENTED INFORMATION

On November 4, 2011, the Company ceased all operations on its drug development business and adopted a new corporate development strategy that changed the business operation of the Company to digital media and digital education with an intense focus on China. Results of operations are reported on a consolidated basis for segment reporting purposes. Consolidated disclosures about revenue streams and long-lived assets by geographic area are seen below.

 

Revenues

 

The Company did not generate revenue for the years 2016, 2015 and 2014. The Company derived revenues from royalties and from consulting services for the years ended September 30, 2014 and 2013.

 

    Years ended September 30,  
Revenue Stream   2016     2015     2014  
Disposal of Indaflex rights (Mexico Only)   $ 0     $ 0     $ 0  
Consulting Fees (North America)     -       -       -  
Gross Operating Revenue     0       0       0  
                         
Other non-operating revenue:                        
Forgone Accounts Payable     -       20,227       13,364  
Gain from disposal of fixed assets     -       -       -  
Legal Settlement     -       -       -  
Interest Income     67       416       409  
                         
Total Revenues and Non-Operating Revenues   $ 67     $ 20,373     $ 13,773  

 

    As of September 30,
Long Lived Assets   2016     2015     2014  
North America   $ -     $ -     $ -  
Asia     5,879       10,874       15,706  
Total Long Lived Assets   $ 5,879     $ 10,874     $ 15,706